Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...

The likelihood of experiencing an increase in Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index within 208 weeks was lower for patients in the ...

AZ said in the summer that anifrolumab had met its objectives in the phase 3 TULIP-2 trial, around a year after it flunked an earlier study (TULIP-1) which had caused many to dismiss any prospect ...

Anifrolumab was all-but written off in 2018 after failing the phase 3 TULIP-1 trial, but bounced back ... despite earlier reservations that its mixed clinical results might stand in the way ...

For the trial, researchers compared 354 patients prescribed anifrolumab against 561 patients who received the usual care for lupus. All of these patients participated in the clinical trials that ...

Last November, results from the MITIGATE trial made headlines at ACR Convergence ... according to data published in The Lancet Rheumatology. Adding anifrolumab to standard treatment for systemic ...

Indeed a ground-breaking successful anifrolumab study used a steroid tapering component ... novel design of prospective clinical trials in SLE, and critical teaching of the proper use of activity ...